Plaque angiogenesis and intraplaque hemorrhage in atherosclerosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Acute cardiovascular events, due to rupture or erosion of an atherosclerotic plaque, represent the major cause of morbidity and mortality in patients. Growing evidence suggests that plaque neovascularization is an important contributor to plaque growth and instability. The vessels' immaturity, with profound structural and functional abnormalities, leads to recurrent intraplaque hemorrhage. This review discusses new insights of atherosclerotic neovascularization, including the effects of leaky neovessels on intraplaque hemorrhage, both in experimental models and humans. Furthermore, modalities for in vivo imaging and therapeutic interventions to target plaque angiogenesis will be discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · cited 1×
“Blood fl ow plays crucial roles in angiogenesis by generating frictional force that develops between fl owing blood and the vascular endothelium (Sewduth and Santoro, 2016).”
BackgroundMolecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467 · cited 2×
“VEGF and its main receptors VEGFR-1 and VEGFR-2 drive EC proliferation and tube formation as well as the attachment and detachment of pericytes during the maturation of neovessels (Carmeliet and Jain, 2011).”
BackgroundEndostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486 · cited 2×
“Endostar is a novel modi fi ed recombinant human endostatin (O'Reilly et al., 1997) a broad-spectrum angiogenesis inhibitor that interferes with the pro-angiogenic action of growth factors such as basic fi broblast growth factor (bFGF/FGF-2) and VEGF.”
BackgroundRegulation of angiogenesis by hypoxia: role of the HIF system
Pugh, C. W., & Ratcliffe, P. J. (2003) · Nature Medicine · doi:10.1038/nm0603-677 · Cited by 2,520
Hypoxia signalling in cancer and approaches to enforce tumour regression
Pouysségur, J., Dayan, F., & Mazure, N. M. (2006) · Nature · doi:10.1038/nature04871 · Cited by 1,676 · cited 3×
“5% CO2) oxygenation, plaque growth was inhibited (Pouyssegur et al., 2006).”
BackgroundAntiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
Asparagine Hydroxylation of the HIF Transactivation Domain: A Hypoxic Switch
Lando, D., Peet, D. J., Whelan, D. A., Gorman, J. J., & Whitelaw, M. L. (2002) · Science · doi:10.1126/science.1068592 · Cited by 1,558 · cited 1×
“Under normoxic conditions, the synthesized HIF-1 α is rapidly degraded and the co-activators are blocked by oxygen-dependent enzymes; the prolyl-hydroxylases domain (PHD) enzymes (Lando et al., 2002a, 2002b).”
BackgroundLando, D., Peet, D. J., Gorman, J. J., Whelan, D. A., Whitelaw, M. L., & Bruick, R. K. (2002) · Genes & Development · doi:10.1101/gad.991402 · Cited by 1,550 · cited 1×
“Under normoxic conditions, the synthesized HIF-1 α is rapidly degraded and the co-activators are blocked by oxygen-dependent enzymes; the prolyl-hydroxylases domain (PHD) enzymes (Lando et al., 2002a, 2002b).”
BackgroundTian, H., McKnight, S. L., & Russell, D. W. (1997) · Genes & Development · doi:10.1101/gad.11.1.72 · Cited by 1,351
HIF transcription factors, inflammation, and immunity
Palazon, A., Goldrath, A. W., Nizet, V., & Johnson, R. S. (2014) · Immunity · doi:10.1016/j.immuni.2014.09.008 · Cited by 1,195 · cited 1×
“They have common activating stimuli and share regulators and targets (Palazon et al., 2014; D'Ignazio et al., 2016).”
BackgroundFantin, A., Vieira, J. M., Gestri, G., Denti, L., Schwarz, Q., Prykhozhij, S., Peri, F., Wilson, S. W., & Ruhrberg, C. (2010) · Blood · doi:10.1182/blood-2009-12-257832 · Cited by 1,153 · cited 1×
“It was shown in zebra fi sh embryos that macrophages can act as cellular chaperones for endothelial cell fusion by bridging tip cells from di ff erent vessel segments (Fantin et al., 2010).”
BackgroundMacrophage Phenotype and Function in Different Stages of Atherosclerosis
Tabas, I., & Bornfeldt, K. E. (2016) · Circulation Research · doi:10.1161/circresaha.115.306256 · Cited by 1,121 · cited 1×
“This malfunc-tioning increases the in fl ammation state and reduces cholesterol e ffl ux contributing to necrotic core expansion and ultimately, the increase of risk of plaque rupture (Tabas and Bornfeldt, 2016).”
BackgroundRegulation of hypoxia-inducible factor-1α by NF-κB
van Uden, P., Kenneth, N. S., & Rocha, S. (2008) · Biochemical Journal · doi:10.1042/bj20080476 · Cited by 729
CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis
Kojima, Y., Volkmer, J.-P., McKenna, K., Civelek, M., Lusis, A. J., Miller, C. L., Direnzo, D., Nanda, V., Ye, J., Connolly, A. J., et al. (2016) · Nature · doi:10.1038/nature18935 · Cited by 683
Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis
Yahagi, K., Kolodgie, F. D., Otsuka, F., Finn, A. V., Davis, H. R., Joner, M., & Virmani, R. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.164 · Cited by 548 · cited 3×
“Human atherosclerotic lesions in saphenous vein bypass grafts are vulnerable and have a higher risk to disrupt than native atherosclerotic lesions (de Vries et al., 2016; Yahagi et al., 2016).”
BackgroundPhagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis
Schrijvers, D. M., De Meyer, G. R. Y., Kockx, M. M., Herman, A. G., & Martinet, W. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000166517.18801.a7 · Cited by 509
Genesis and growth of extracellular-vesicle-derived microcalcification in atherosclerotic plaques
Hutcheson, J. D., Goettsch, C., Bertazzo, S., Maldonado, N., Ruiz, J. L., Goh, W., Yabusaki, K., Faits, T., Bouten, C., Franck, G., et al. (2016) · Nature Materials · doi:10.1038/nmat4519 · Cited by 419
Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.
Goel, S., Wong, A. H.-K., & Jain, R. K. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006486 · Cited by 352
Ozaki, M., Kawashima, S., Yamashita, T., Hirase, T., Namiki, M., Inoue, N., Hirata, K.-I., Yasui, H., Sakurai, H., Yoshida, Y., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215215 · Cited by 268
Tetrahydrobiopterin in Cardiovascular Health and Disease
Bendall, J. K., Douglas, G., McNeill, E., Channon, K. M., & Crabtree, M. J. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5566 · Cited by 231 · cited 2×
“However, clinical trials in patients with coronary heart disease and myocardial infarction have shown mixed results for BH 4 supplementation (Bendall et al., 2014).”
BackgroundEndothelial Cilia Mediate Low Flow Sensing during Zebrafish Vascular Development
Goetz, J. G., Steed, E., Ferreira, R. R., Roth, S., Ramspacher, C., Boselli, F., Charvin, G., Liebling, M., Wyart, C., Schwab, Y., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.01.032 · Cited by 219
Cited by
Alternative macrophages in atherosclerosis: not always protective!
Pourcet, B., & Staels, B. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120123 · Cited by 62
Metadata
- Authors
- Parma, L., Baganha, F., Quax, P. H. A., & de Vries, M. R.
- Venue
- European Journal of Pharmacology
- Publisher
- Elsevier BV
- Published
- 2017-12
- Volume
- 816
- Pages
- 107-115
- ISSN
- 0014-2999 (ISSN-L)
- OpenAlex
- W2605484715
- Cited by
- 181
- References
- 21
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.